Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.
World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of molecular diagnostic kits.
Biofortuna is an ISO 13485 certified company based in the UK, with state-of-the-art FDA registered facilities, including molecular biology laboratories. The company uniquely offers a strong scientific basis to its manufacturing services, giving customers a level of understanding and flexibility, in regulatory issues as well as development and manufacturing challenges, that few IVD contract manufacturers can boast.
Dr Simon Douglas, CEO of Biofortuna, said: “We pride ourselves on understanding our customers’ requirements and custom designing projects to meet their needs. Our recent expansion and restructuring builds on this successful approach, and we look forward to providing existing and future customers with a broad portfolio of services.”
For further information, visit booth #4565 at the AACC, contact firstname.lastname@example.org or visit www.biofortuna.com.
Comments are closed.